3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
NET
8
Gastrointestinal
8
Endocrine
8
Lymphoid
2
CNS
2
Sarcoma
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
238
Lymphoma
235
Lymphoma, Non-Hodgkin
203
Leukemia, Lymphocytic, Chronic, B-Cell
186
Lymphoma, Large B-Cell, Diffuse
178
Lymphoma, Follicular
173
Lymphoma, B-Cell
112
Lymphoma, Mantle-Cell
107
Hodgkin Disease
105
Leukemia, Myeloid, Acute
102
Recurrence
97
Multiple Myeloma
91
Burkitt Lymphoma
90
Leukemia
76
Neoplasms
68
Lymphoma, B-Cell, Marginal Zone
60
Hematologic Neoplasms
59
Myelodysplastic Syndromes
56
Waldenstrom Macroglobulinemia
48
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
43
Lymphoma, T-Cell
42
Lymphoma, T-Cell, Peripheral
36
Lymphoma, T-Cell, Cutaneous
31
Leukemia, Biphenotypic, Acute
31
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
29
Leukemia, B-Cell
26
Mycosis Fungoides
25
Lymphoma, Large-Cell, Anaplastic
25
Sarcoma
23
Breast Neoplasms
22
Interventions
pasireotide
1
amino-acid, glucose, and electrolyte solution
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
Lymphoid
×
90 days
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled
NCT06784752
2026-04-30
NETTER-3
Novartis
Phase 3
Recruiting
240 enrolled